| Literature DB >> 35444879 |
Dimitrios Vasileiadis1, Georgios Drosos2, Georgios Charitoudis2, Ismene A Dontas3, John Vlamis4.
Abstract
PURPOSE: Several studies have shown that patients with severe osteoarthritis (OA) of the knee can reduce their knee pain, improve their quadriceps strength, and improve their functional ability through regular exercise training. The purpose of this study was to investigate the efficacy of a six-week supervised high-intensity preoperative training program on muscle strength, functional performance, and patient-reported outcomes in patients undergoing total knee arthroplasty (TKA).Entities:
Keywords: knee function; osteoarthritis; physiotherapy; preoperative rehabilitation; total knee arthroplasty
Year: 2022 PMID: 35444879 PMCID: PMC9010031 DOI: 10.7759/cureus.23191
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Flow diagram of the progress through the phases of the study
Demographic characteristics of participants
| Intervention group (n=44) | Control group (n=44) | P-value | |
| Age (years) | 68.7±5.2 (61–81) | 68.9±5.4 (60–79) | 0.658 |
| Female gender | 24 (54.5%) | 26 (59.1%) | 0.667 |
| No comorbidities | 11 (25%) | 10 (22.73%) | 0.803 |
| BMI (kg/m2) | 31±4.1 (27–43) | 30±3.9 (28–41) | 0.851 |
| WOMAC | 44.68±11.97 | 45.32±10.95 | 0.795 |
| SF-36 | 34.25±9.48 | 34.30±9.39 | 0.947 |
| KOOS | 31.98±9.24 | 34.61±8.85 | 0.091 |
Scores for all the questionnaires
| Variable | Assessment time | Mean control group | Mean (± SD) intervention group | P-value |
| Womac score | Baseline | 45.32±10.95 | 44.68±11.97 | 0.795 |
| Pre-op | 44.11±11.19 | 33.75±10.23 | <0.001 | |
| 4 weeks post-op | 30.16±7.44 | 23.28±5.50 | <0.001 | |
| 12 weeks post-op | 30.52±7.16 | 24.77±5.89 | <0.001 | |
| SF-36 | Baseline | 34.30±9.39 | 34.25±9.48 | 0.947 |
| Pre-op | 36.73±8.54 | 47.20±9.20 | <0.001 | |
| 4 weeks post-op | 48.02±10.08 | 57.70±7.70 | <0.001 | |
| 12 weeks post-op | 51.52±9.59 | 56.66±8.76 | 0.006 | |
| KOOS | Baseline | 34.61±8.85 | 31.98±9.24 | 0.091 |
| Pre-op | 35.93±8.89 | 41.84±8.68 | 0.001 | |
| 4 weeks post-op | 57.68±10.86 | 58.09±8.39 | 0.844 | |
| 12 weeks post-op | 60.66±10.76 | 60.61±9.80 | 0.984 |
Means and differences between intervention and control group at each test point in WOMAC, SF-36, and KOOS questionnaires
| Variable | Assessment time | Mean control group | Mean (± SD) intervention group | P-value |
| WOMAC | Baseline | 45.32±10.95 | 44.68±11.97 | 0.795 |
| Pre-op Test 1 (mean±SD) | 44.11±11.19 | 33.75±10.23 | <0.001 | |
| Δ Baseline - Test 1 Mean (95% CI) | −1.21 (−5.90, 3.48) | −10.93 (−15.65, −6.21) | <0.001 | |
| 4 weeks post-op (Test 2) (mean±SD) | 30.16±7.44 | 23.28±5.50 | <0.001 | |
| Δ Baseline - Test 2 Mean (95% CI) | −15.16 (−19.13, −11.19) | −21.41 (−25.34, −17.45) | 0.001 | |
| 12 weeks post-op - Test 3 (mean±SD) | 30.52±7.16 | 24.77±5.89 | <0.001 | |
| Δ Baseline - Test 3 Mean (95% CI) | −14.80 (−18.72, −10.88) | −19.91 (−23.91, −15.91) | 0.007 | |
| SF-36 | Baseline | 34.30±9.39 | 34.25±9.48 | 0.947 |
| Pre-op Test 1 (mean±SD) | 36.73±8.54 | 47.20±9.20 | <0.001 | |
| Δ Baseline - Test 1 Mean (95% CI) | 2.43 (−1.38, 6.23) | 12.95 (8.99, 16.91) | <0.001 | |
| 4 weeks post-op (Test 2) (mean±SD) | 48.02±10.08 | 57.70±7.70 | <0.001 | |
| Δ Baseline - Test 2 Mean (95% CI) | 13.72 (9.59, 17.85) | 23.45 (19.79, 27.11) | <0.001 | |
| 12 weeks post-op - Test 3 (mean±SD) | 51.52±9.59 | 56.66±8.76 | 0.006 | |
| Δ Baseline - Test 3 Mean (95% CI) | 17.22 (13.20, 21.24) | 22.41 (18.54, 26.28) | 0.004 | |
| KOOS | Baseline | 34.61±8.85 | 31.98±9.24 | 0.091 |
| Pre-op Test 1 (mean±SD) | 35.93±8.89 | 41.84±8.68 | 0.001 | |
| Δ Baseline - Test 1 Mean (95% CI) | 1.32 (−2.44, 5.08) | 9.86 (6.06, 13.66) | <0.001 | |
| 4 weeks post-op (Test 2) (mean±SD) | 57.68±10.86 | 58.09±8.39 | 0.844 | |
| Δ Baseline - Test 2 Mean (95% CI) | 23.07 (18.87, 27.27) | 26.11 (22.37, 29.85) | 0.048 | |
| 12 weeks post-op - Test 3 (mean±SD) | 60.66±10.76 | 60.61±9.80 | 0.984 | |
| Δ Baseline - Test 3 Mean (95% CI) | 26.05 (21.87, 30.23) | 28.63 (24.59, 32.67) | 0.087 |
Scores for all physical measures at assessment points
| Variable | Assessment time | Mean control group | Mean (± SD) intervention group | P-value |
| Quadriceps strength | Baseline | 0.88±0.07 | 0.86±0.07 | 0.754 |
| Pre-op | 0.86±0.09 | 0.92±0.10 | <0.001 | |
| 4 weeks post-op | 0.70±0.05 | 0.75±0.08 | 0.078 | |
| 12 weeks post-op | 0.87±0.11 | 0.93±0.11 | 0.134 | |
| 20 meters walk test | Baseline | 19.00±1,20 | 18.66±0.97 | 0.179 |
| Pre-op | 18.96±1.12 | 18.31±0.82 | 0.004 | |
| 4 weeks post-op | 18.19±089 | 17.60±0.73 | 0.002 | |
| 12 weeks post-op | 17.83±0.79 | 17.18±0.64 | <0.001 | |
| 30-sec chair stand test | Baseline | 12.02±1.30 | 12.43±1.26 | 0.214 |
| Pre-op | 12.04±1.27 | 12.82±1.23 | 0.005 | |
| 4 weeks post-op | 12.95±1.22 | 13.93±1.13 | 0.001 | |
| 12 weeks post-op | 13.20±1.13 | 14.36±0.99 | <0.001 |
Means and differences between intervention and control group at each test point in functional performance and muscle strength outcomes
| Variable | Assessment time | Mean control group | Mean (± SD) intervention group | P-value |
| Quadriceps strength | Baseline | 0.88±0.07 | 0.86±0.07 | 0.754 |
| Pre-op Test 1 (mean±SD) | 0.86±0.09 | 0.92±0.10 | <0.001 | |
| Δ Baseline - Test 1 mean (95% CI) | 0.02 (−0.01, 0.05) | 0.06 (0.02, 0.10) | <0.001 | |
| 4 weeks post-op (Test 2) (mean±SD) | 0.70±0.05 | 0.75±0.08 | 0.078 | |
| Δ Baseline - Test 2 mean (95% CI) | −0.18 (−0.15, −0.21) | −0.11 (−0.08, −0.14) | 0.001 | |
| 12 weeks post-op - Test 3 (mean±SD) | 0.87±0.11 | 0.93±0.11 | 0.134 | |
| Δ Baseline - Test 3 mean (95% CI) | −0.01 (−0.03, 0.05) | 0.07 (0.03, 0.11) | 0.009 | |
| 20-meter walk test | Baseline | 19.00±1.20 | 18.66±0.97 | 0.179 |
| Pre-op Test 1 (mean±SD) | 18.96±1.12 | 18.31±0.82 | 0.004 | |
| Δ Baseline - Test 1 mean (95% CI) | −0.04 (−0.45, 0.53) | −0.35 (−0.72, 0.03) | <0.001 | |
| 4 weeks post-op (Test 2) (mean±SD) | 18.19±0.89 | 17.64±0.73 | 0.002 | |
| Δ Baseline - Test 2 mean (95% CI) | 0.81 (0.36, 1.26) | 1.02 (0.66, 1.38) | 0.023 | |
| 12 weeks post-op - Test 3 (mean±SD) | 17.83±0.79 | 17.28±0.64 | <0.001 | |
| Δ Baseline - Test 3 mean (95% CI) | 1.17 (0.74–1.60) | 1.38 (1.03, 1.73) | 0.032 | |
| 30-sec chair stand test | Baseline | 12.02±1.30 | 12.43±1.26 | 0.214 |
| Pre-op Test 1 (mean±SD) | 12.04±1.27 | 12.82±1.23 | 0.005 | |
| Δ Baseline –Test 1 mean (95% CI) | 0.02 (−0.52, 0.54) | 0.39 (0.14, 0.92) | 0.001 | |
| 4 weeks post-op (Test 2) (mean±SD) | 12.95±1.22 | 13.93±1.13 | 0.001 | |
| Δ Baseline - Test 2 mean (95% CI) | 0.93 (0.40, 1.96) | 1.50 (0.99, 2.00) | <0.001 | |
| 12 weeks post-op - Test 3 (mean±SD) | 13.20±1.13 | 14.36±0.99 | <0.001 | |
| Δ Baseline –Test 3 mean (95% CI) | 1.18 (0.66, 1.70) | 1.93 (1.45, 2.41) | <0.001 |